tyramine has been researched along with Parkinson Disease, Secondary in 2 studies
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Da Prada, M | 1 |
| Kettler, R | 1 |
| Keller, HH | 1 |
| Bonetti, EP | 1 |
| Imhof, R | 1 |
| Youdim, MB | 1 |
| Finberg, JP | 1 |
2 other studies available for tyramine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Ro 16-6491: a new reversible and highly selective MAO-B inhibitor protects mice from the dopaminergic neurotoxicity of MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzamides; Brain; Corpus Striatum; Dopamine; | 1987 |
MAO type B inhibitors as adjunct to L-dopa therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkynes; Animals; Brain; Drug Therapy, Combination; Hu | 1987 |